Easy discrimination of hematogones from lymphoblasts in B‐cell progenitor acute lymphoblastic leukemia patients using <scp>CD</scp>81/<scp>CD</scp>58 expression ratio

Nagant, Carole; Casula, Daniele; Janssens, Anne; Nguyen, Vo Thanh Phuong; Cantinieaux, Brigitte

doi:10.1111/ijlh.12912

Cited by 18 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, due to the presence of hematogones, it may be difficult to distinguish leukemic lymphoblasts in the diagnosis and follow-up of BCP-ALL. The use of the CD81/CD58 ratio as the discriminating marker enhances the difference between leukemia lymphoblasts and hematogones with high sensitivity and specificity in patients with BCP-ALL ( 196 ).…”

Section: Hematological Malignanciesmentioning

confidence: 99%

CD58 Immunobiology at a Glance

et al. 2021

View full text Add to dashboard Cite

The glycoprotein CD58, also known as lymphocyte-function antigen 3 (LFA-3), is a costimulatory receptor distributed on a broad range of human tissue cells. Its natural ligand CD2 is primarily expressed on the surface of T/NK cells. The CD2-CD58 interaction is an important component of the immunological synapse (IS) that induces activation and proliferation of T/NK cells and triggers a series of intracellular signaling in T/NK cells and target cells, respectively, in addition to promoting cell adhesion and recognition. Furthermore, a soluble form of CD58 (sCD58) is also present in cellular supernatant in vitro and in local tissues in vivo. The sCD58 is involved in T/NK cell-mediated immune responses as an immunosuppressive factor by affecting CD2-CD58 interaction. Altered accumulation of sCD58 may lead to immunosuppression of T/NK cells in the tumor microenvironment, allowing sCD58 as a novel immunotherapeutic target. Recently, the crucial roles of costimulatory molecule CD58 in immunomodulation seem to be reattracting the interests of investigators. In particular, the CD2-CD58 interaction is involved in the regulation of antiviral responses, inflammatory responses in autoimmune diseases, immune rejection of transplantation, and immune evasion of tumor cells. In this review, we provide a comprehensive summary of CD58 immunobiology.

show abstract

Section: Hematological Malignanciesmentioning

confidence: 99%

CD58 Immunobiology at a Glance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…CD58 and CD81 are two important markers that can be used to improve the distinction between HGs and precursor B lymphoblasts. It was recommended that CD58 and CD81 should be included in flow cytometry panels done at the time of diagnosis, thus allowing reliable and rapid MRD monitoring, especially for patients with no aberrant markers on their lymphoblasts [ 10 ]. Another useful marker is CD38.…”

Section: Discussionmentioning

confidence: 99%

Unusual B-Lymphoid Blastic Crisis as Initial Presentation of Chronic Myeloid Leukemia Imposes Diagnostic Challenges

Momen

Baysal

Sait

et al. 2022

Case Reports in Hematology

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder, characterized by reciprocal translocation t(9,22) (q34; q11), leading to increased myeloid proliferation. Most cases are diagnosed in the chronic phase (CP). However, a minority of cases can be present in the blastic phase (BP). In most patients with CML-BP, the blasts have a myeloid phenotype, however, in 20–30% of cases, the blasts have a lymphoid phenotype, mostly a B-cell phenotype. It is challenging to differentiate CML B-lymphoblastic phase (CML-BLP) from Ph + primary B-acute lymphoblastic leukemia (B-ALL) especially when the CML-BLP is the initial presentation of the disease, which is uncommon. We report here an unusual case of CML-BLP as an initial presentation of the disease without typical CML morphological findings. This case demonstrates diagnostic challenges and emphasizes the importance of an integrated approach using morphology, multiparametric flow cytometry, cytogenetic studies, and molecular studies to render an accurate diagnosis.

show abstract

“…Under physiological conditions, CD81 is expressed in the surface of mature B and T cells, for which it is considered a molecule associated with lymphocyte maturation. Therefore, CD81 may be detectable from the early stages of lymphopoiesis, and its density increases as populations mature [43][44][45] . The absence of CD81 expression and positivity to other markers, such as CD58, marks suspiciously malignant populations 44 .…”

Section: Cd81mentioning

confidence: 99%

“…Therefore, CD81 may be detectable from the early stages of lymphopoiesis, and its density increases as populations mature [43][44][45] . The absence of CD81 expression and positivity to other markers, such as CD58, marks suspiciously malignant populations 44 . Thus, the combination allows identifying residual blastic clones from developing normal progenitors (hematogones) (Fig.…”

Section: Cd81mentioning

confidence: 99%

Molecular and cellular markers for measurable residual disease in acute lymphoblastic leukemia

Juárez-Avendaño¹,

Méndez‐Ramírez²,

Luna-Silva³

et al. 2021

BMHIM

View full text Add to dashboard Cite

Acute leukemia is the leading cause of death in children worldwide, particularly in developing countries where the growing number of cases with unfavorable prognosis and high risk of early relapse have positioned pediatric cancer as a priority. The late and imprecise diagnosis, malnutrition and unfavorable environmental conditions, and toxicity-associated therapy are some of the factors that compromise the success of the treatment and affect survival rates in vulnerable regions. An early and exhaustive classification of malignant neoplasms at the clinical debut and the proper follow-up of treatment's response constitute one of the most powerful prognostic factors. Remarkably, the ultrasensitive detection of residual and relapse clones that determine the minimal/measurable residual disease (MRD) has been a milestone in the comprehensive management of hematologic malignancies that favorably improve the complete remission cases. In this review, we discuss the scientific and technological advances applied to laboratory diagnosis in MRD determination: from the multiparametric immunophenotyping to next-generation sequencing and cytomics. As a result of multidisciplinary research in the main concentration oncology centers and laboratories, residual leukemia detection strategies that combine molecular analysis and cellular markers are recommended as the most valuable tools, making them the paradigm for stratification campaigns in vulnerable regions.

show abstract

Easy discrimination of hematogones from lymphoblasts in B‐cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio

Abstract: We demonstrate in this study that routine use of the MFI antigen ratio (CD81/CD58) in addition to the MFC evaluation using WHO classical criteria appears to be an efficient approach to discriminate LB from HG.

Cited by 18 publications

References 22 publications

CD58 Immunobiology at a Glance

CD58 Immunobiology at a Glance

Unusual B-Lymphoid Blastic Crisis as Initial Presentation of Chronic Myeloid Leukemia Imposes Diagnostic Challenges

Molecular and cellular markers for measurable residual disease in acute lymphoblastic leukemia

Contact Info

Product

Resources

About